Anti-human IL6 Recombinant Antibody (mAb 1339) (TAB-674LC) (CAT#: TAB-674LC)

Recombinant monoclonal antibody mAb 1339 is a human monoclonal antibody that specifically binds to human IL-6 and can be potentially used in the treatment of inflammatory diseases and autoimmune diseases.


Specific Inquiry
  • Size:
  • Conjugation:
  • Endotoxin:
  • Purity:
  • Fc Engineering:
  • Published Data
  • Gene Expression
  • Datasheet
  • MSDS
  • COA

Figure 1 mAb 1339 inhibits MM cell proliferation in a time and dose-dependent manner.

Figure 1 mAb 1339 inhibits MM cell proliferation in a time and dose-dependent manner.

(A) IL-6 dependent INA-6 cells were cultured in the presence of murine, chimeric and humanized MAbs to IL-6, to gp130 or to gp80, as well as with isotype control Abs at various concentrations. Cell proliferation was assessed by [3H]thymidine uptake at 72 hours. (B) IL-6 dependent INA6 and XG1 cells were cultured in the presence of fully humanized anti-IL-6 MAb 1339, as well as with isotype Ab control at various concentrations for variable time (24-72 h) at 37°C. Data represent mean +/- SD of 4 independent experiments performed in triplicate. mAb 1339 inhibits IL-6 dependent MM cell growth in a dose dependent manner.

Fulciniti, M., Hideshima, T., Vermot-Desroches, C., Pozzi, S., Nanjappa, P., Shen, Z.,... & Tai, Y. T. (2009). A high-affinity fully human anti–IL-6 mAb, 1339, for the treatment of multiple myeloma. Clinical Cancer Research, 15(23), 7144-7152.

Figure 2 mAb 1339 overcomes the effect of BMSC on both IL-6 dependent and independent MM cell growth.

Figure 2 mAb 1339 overcomes the effect of BMSC on both IL-6 dependent and independent MM cell growth.

(A) INA-6 and XG-1 cells were cultured with BMSC and in the presence of isotype Ab control as well as different doses of mAb 1339 for 24-72 hours. Cell proliferation was assessed by [3H]thymidine uptake assay and presented as % change from control. (B) MM1S, MM1R and U266 cells were cultured with BMSC or 5 ng/ml of rIL-6 with and without 1 μg/ml of mAb 1339, for 48 hours. DNA synthesis was assessed by [³H] thymidine uptake assay and presented as counts per minute (cpm). (C) Primary CD138+ MM cells were incubated in the absence or presence of BMSC with and without mAb 1339 for 24 hours. mAb 1339 is able to overcome the promoting effects of BMSC on MM cell growth.

Fulciniti, M., Hideshima, T., Vermot-Desroches, C., Pozzi, S., Nanjappa, P., Shen, Z.,... & Tai, Y. T. (2009). A high-affinity fully human anti–IL-6 mAb, 1339, for the treatment of multiple myeloma. Clinical Cancer Research, 15(23), 7144-7152.

Figure 3 1339 inhibits STAT3, ERK1,2 and Akt signaling pathways.

Figure 3 1339 inhibits STAT3, ERK1,2 and Akt signaling pathways.

MM1S cells were incubated with (A) IL-6 (5 ng/ml, 10 and 30 minutes) or (B) with BMSC supernatant (30 minutes) in the absence or presence of 0.1 and 1 ug/ml of mAb 1339. Cells were harvested and whole cell lysates were subjected to immunoblotting using indicated Abs. 1339 inhibits both IL-6- and BMSC-induced activation of ERK 1, 2 and STAT3 pathway in MM cells, while a relatively lesser effect was observed with activation of AKT, as shown by densitometric quantitation of band intensity from WB (C).

Fulciniti, M., Hideshima, T., Vermot-Desroches, C., Pozzi, S., Nanjappa, P., Shen, Z.,... & Tai, Y. T. (2009). A high-affinity fully human anti–IL-6 mAb, 1339, for the treatment of multiple myeloma. Clinical Cancer Research, 15(23), 7144-7152.

Figure 4 mAb 1339 enhances growth inhibitory effect of anti-MM agents in the context of BMSC

Figure 4 mAb 1339 enhances growth inhibitory effect of anti-MM agents in the context of BMSC

INA-6 and MM1S cells were cultured with BMSC in the absence or presence of mAb 1339 (1 μg/ml) and dexamethasone (1 μM), velcade (5nM), perifosine (2.5 μM), revlimid (5 μM) with (1 μg/ml) or without mAb 1339 for 48 hours. DNA synthesis was assessed by [³H] thymidine uptake assay and presented as % of control cells without mAb 1339 or other agents. The combination of mAb 1339 and other anti-MM agents resulted in significant (p < 0.05) and synergistic antiproliferative effect.

Fulciniti, M., Hideshima, T., Vermot-Desroches, C., Pozzi, S., Nanjappa, P., Shen, Z.,... & Tai, Y. T. (2009). A high-affinity fully human anti–IL-6 mAb, 1339, for the treatment of multiple myeloma. Clinical Cancer Research, 15(23), 7144-7152.

Figure 5 Additive in vivo effect of MAb 1339 in combination with dexamethasone in a murine model of human MM (SCID-hu).

Figure 5 Additive in vivo effect of MAb 1339 in combination with dexamethasone in a murine model of human MM (SCID-hu).

(A) mAb 1339 (100 μg per mouse) was injected intraperitoneal (i.p.) in SCID mice and its pharmacokinetics was evaluated by quantification of MAbs concentration in serum. After a single injection of mAb 1339, peak serum levels were observed after 24 hours and the MAbs remained in circulation for more than 15 days. (B) After injection of INA-6 MM cells directly into the human bone implant, SCID-hu mice were monitored for productiron of shuIL-6R in murine sera as a marker for MM cell growth. After the first detection of shuIL-6R, mice were injected with isotype control (100 μg per mouse, 1×/week) (n=6), mAb 1339 (100 μg per mouse, 1×/week) (n=4), dexamethasone (1mg/kg, 3×/week) (n=4), or mAb 1339 plus dexamethasone (n=4). Baseline values before treatment were not significantly different among groups.

Fulciniti, M., Hideshima, T., Vermot-Desroches, C., Pozzi, S., Nanjappa, P., Shen, Z.,... & Tai, Y. T. (2009). A high-affinity fully human anti–IL-6 mAb, 1339, for the treatment of multiple myeloma. Clinical Cancer Research, 15(23), 7144-7152.

Figure 6 Effect of 1339 on osteoclastogenesis in vitro and bone remodeling in vivo.

Figure 6 Effect of 1339 on osteoclastogenesis in vitro and bone remodeling in vivo.

(A) In order to evaluate the effect of inhibition of IL-6 by 1339 on osteoclast differentiation, human pre-OCs were stimulated with OC differentiation media in presence and absence of IL-6 with or without 1 μg/ml of isotype control or mAb 1339 for 7 days. At the end of the treatment period, cells were fixed, stained for TRAP and counted. Data are expressed as mean +/- SD and are presented as percentage change from control. (B-C) To evaluate the effects of 1339 on the bone compartment, SCID-hu mice were injected with INA-6 cells into the implanted bone and were treated with isotype control or mAb 1339 after first detection of tumor. One month after treatment, bone chips were retrieved and analyzed by micro-CT and histological examination. (B) A qualitative assessment of images obtained from micro-CT suggests resistance to osteolytic bone destruction by mAb 1339. (C) H&E staining showed increased bone tissue and decreased MM cell number in the treated samples compared to controls.

Fulciniti, M., Hideshima, T., Vermot-Desroches, C., Pozzi, S., Nanjappa, P., Shen, Z.,... & Tai, Y. T. (2009). A high-affinity fully human anti–IL-6 mAb, 1339, for the treatment of multiple myeloma. Clinical Cancer Research, 15(23), 7144-7152.


Specifications

  • Host Species
  • Human
  • Type
  • Human antibody
  • Specificity
  • Human
  • Clone
  • mAb 1339
  • Applications
  • ELISA, FC, Inhib, FuncS
  • Related Disease
  • Inflammatory disease and autoimmune disease

Applications

  • Application Notes
  • The antibody was validated for Inhibition and Function assay. For details, refer to Published Data.

Target

  • Alternative Names
  • IL6; interleukin 6; HGF; HSF; BSF2; IL-6; IFNB2; interleukin-6; CDF; BSF-2; IFN-beta-2; interferon beta-2; interleukin BSF-2; interferon, beta 2; hybridoma growth factor; CTL differentiation factor; B-cell stimulatory factor 2; B-cell differentiation factor

Related Resources

  • Related Diseases
  • Related Signaling Pathways

Product Notes

This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:

• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production

See more details about Hi-Affi™ recombinant antibody benefits.

Downloads

Download resources about recombinant antibody development and antibody engineering to boost your research.

See other products for "Clone mAb 1339"

See other products for "IL6"

Chimeric Antibody

CAT Product Name Application Type
TAB-0026CL Human Anti-IL6 Recombinant Antibody (TAB-0026CL) Elisa, In vivo, FuncS, Block Chimeric (mouse/human) IgG
TAB-0026CL-F(E) Human Anti-IL6 Recombinant Antibody; Fab Fragment (TAB-0026CL-F(E)) Elisa, In vivo, FuncS, Block Chimeric (mouse/human) Fab
TAB-670LC Anti-human IL6 Recombinant Antibody (NTS) (TAB-670LC) ELISA, Inhib Chimeric antibody (mouse/human)
TAB-670LC-F(E) Anti-human IL6 Fab Fragment (NTS) ELISA Chimeric antibody (mouse/human)
VS3-WK1519 Human Anti-IL6 Recombinant Antibody (clone CLLB8) ELISA, FC Chimeric (mouse/human) IgG1

Humanized Antibody

Fab Glycosylation

CAT Product Name Application Type
Gly-037LC Recombinant Anti-Human IL6 Antibody (Fab glycosylation) ELISA Humanized antibody

Deglycosylated Antibody (Non-glycosylated IgGs)

CAT Product Name Application Type
Gly-197LC Recombinant Anti-Human IL6 Antibody (Non-glycosylated) ELISA Humanized antibody

Chicken IgY Antibody

CAT Product Name Application Type
BRD-0284MZ Chicken Anti-Interleukin-6 Polyclonal IgY WB, Indirect ELISA Chicken antibody

Neutralizing Antibody

Blocking Antibody

CAT Product Name Application Type
NEUT-1474CQ Rat Anti-Il6 Recombinant Antibody (clone 32C11) Block, ELISA, WB Rat IgG2a

MHC Tetramer for Cancer

ADCC Enhanced Antibody

CAT Product Name Application Type
AFC-TAB-239 Afuco™ Anti-IL6 ADCC Recombinant Antibody (Elsilimomab), ADCC Enhanced FuncS, IF, Neut, ELISA, FC ADCC enhanced antibody
AFC-TAB-097 Afuco™ Anti-IL6 ADCC Recombinant Antibody (Sirukumab), ADCC Enhanced FC, IP, ELISA, Neut, FuncS, IF ADCC enhanced antibody
AFC-TAB-H26 Afuco™ Anti-IL6 ADCC Recombinant Antibody (Enlimomab), ADCC Enhanced Neut, ELISA, IF, IP, FuncS, FC ADCC enhanced antibody
AFC-TAB-253 Afuco™ Anti-IL6 ADCC Recombinant Antibody (Olokizumab), ADCC Enhanced ELISA, FC, IP, FuncS, IF ADCC enhanced antibody

Customer Reviews and Q&As

Submit a review or a question
There are currently no Customer reviews or questions for TAB-674LC. Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.

For Research Use Only. Not For Clinical Use.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Send Inquiry

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

© 2024 Creative Biolabs.
  • 0
  • 0
Cart

    Go to compare